Helus Pharma (HELP)
Company Profile
HELP Stock Chart
Helus Pharma is building what Big Pharma has failed to deliver for decades: next-generation novel compounds designed to treat serious mental health disorders where outdated drugs have repeatedly fallen short. Using advanced molecular engineering, Helus Pharma is developing drug candidates aimed squarely at major unmet needs — starting with major depressive disorder and generalized anxiety disorder.
Helus Pharma’s two lead molecules, HLP003 and HLP004, have both cleared Phase 2 clinical trials. HLP003 has advanced into Phase 3, the final step before potential approval, with HLP004 positioned close behind. The company also controls a growing pipeline protected by a powerful intellectual property moat, with over 350 patents pending and more than 100 already granted.
Helus Pharma has two powerful paths forward: continue building value as an independent pharmaceutical company or become a highly attractive acquisition target for a major drugmaker.
Eight Surprising Reasons Why Helus Pharma Could Be a Profitable Investment Opportunity for You
Reason #1: Clinical Studies are Already Bringing Positive Results for Helus’s Flagship Drugs
Reason #2: Millions of people around the world are desperate for the relief Helus Pharma’s new drugs in
development could offer … and that could, if and when approved, send sales and profits flying
Reason #3: RFK Jr. is leading the charge to open up the world to new therapies
Reason #4: The FDA’s “Golden Ticket” Is Clearing the Way for Breakthrough New Therapies
Reason #5: Helus Pharma is Building a Robust New Drug Pipeline
Reason #6: Helus Pharma Boasts World Class Leadership and Has Plenty Of Cash
Reason #7: Big Pharma Faces a “Patent Cliff” that Could Spur a Small-Cap Buying Binge
Reason #8: A Surprising Number of Analysts See Good Times Ahead for Helus Pharma
Helus Pharma (HELP)
News
Yahoo News
- A Look At Cybin (HELP) Valuation After Positive Phase 2 HLP004 Anxiety Data
- Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
- Cybin (HELP) Is Down 27.3% After Positive HLP004 GAD Phase 2 Data Reported Is The Thesis Intact?
- Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
Access Top Brokerages
